Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Heart

No studies found 0 · 0%GRADE not reported 1 · 25%Very low 3 · 75%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

It is very uncertain whether evolocumab changes CVD compared with ezetimibe and statins (very low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.66 [0.14, 3.04]
1 study · 218 participants
Very low

All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.43 [0.14, 1.3]
3 studies · 5223 participants
Very low

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

It is very uncertain whether evolocumab changes myocardial infarction compared with ezetimibe and statins (very low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.66 [0.23, 1.85]
3 studies · 5003 participants
Very low

Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 3899 participants
GRADE not reported